Intra-Cellular Therapies (ITCI) Stock Forecast & Price Target

→ Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad)

$75.48

+6.61 (+9.60%)

(As of 06/18/2024 ET)

Intra-Cellular Therapies - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 11 Analyst Ratings

Consensus Price Target

$91.83
21.67% Upside

High Forecast	$120.00
Average Forecast	$91.83
Low Forecast	$77.00

Type	Current Forecast 6/20/23 to 6/19/24	1 Month Ago 5/21/23 to 5/20/24	3 Months Ago 3/22/23 to 3/21/24	1 Year Ago 6/20/22 to 6/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$91.83	$90.17	$81.42	$72.78
Forecasted Upside	21.67% Upside	25.23% Upside	20.44% Upside	28.51% Upside

Get Intra-Cellular Therapies Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

Ad InvestorPlace

Must-See: Elon’s New Invention is Absolutely Insane

Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.

Click here for the full story…

ITCI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ITCI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Intra-Cellular Therapies Stock vs. The Competition

Type	Intra-Cellular Therapies	Medical Companies	S&P 500
Consensus Rating Score	2.91	2.70	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	21.67% Upside	1,068.19% Upside	11.31% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
6/18/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$90.00 ➝ $94.00	+20.75%
6/14/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$120.00 ➝ $120.00	+77.02%
6/12/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$75.00 ➝ $78.00	+12.83%
4/23/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$100.00 ➝ $107.00	+43.14%
4/22/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$82.00 ➝ $96.00	+32.65%
4/17/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$80.00 ➝ $90.00	+15.05%
Get the Latest News and Ratings for ITCI and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.
4/17/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$83.00 ➝ $103.00	+31.66%
4/17/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$82.00 ➝ $91.00	+16.32%
4/17/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$67.00 ➝ $77.00	-1.57%
4/3/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$86.00	+28.99%
8/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$80.00	+35.16%
6/30/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$74.00 ➝ $80.00	+29.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:07 AM ET.

ITCI Forecast - Frequently Asked Questions

What is Intra-Cellular Therapies's stock forecast and purchase recommendation?: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Intra-Cellular Therapies is $91.83, with a high forecast of $120.00 and a low forecast of $77.00. The consensus rating for Intra-Cellular Therapies stock is Moderate Buy based on the current 1 hold rating and 10 buy ratings for ITCI. Learn more on ITCI's analyst rating history.
Do Wall Street analysts like Intra-Cellular Therapies more than its competitors?: Analysts like Intra-Cellular Therapies more than other "medical" companies. The consensus rating score for Intra-Cellular Therapies is 2.91 while the average consensus rating score for "medical" companies is 2.70. Learn more on how ITCI compares to other companies.
Does Intra-Cellular Therapies's stock price have much upside?: According to analysts, Intra-Cellular Therapies's stock has a predicted upside of 26.99% based on their 12-month stock forecasts.